SLC29A1 and adenocarcinoma: Patients with detectable hENT1 expression had significantly longer median survival from gemcitabine initiation than those lacking hENT1 in a proportion of adenocarcinoma cells (median survival, 13 vs 4 months, P=0.01) (Spratlin et al, 2004).